Medacta Group SA
SIX:MOVE

Watchlist Manager
Medacta Group SA Logo
Medacta Group SA
SIX:MOVE
Watchlist
Price: 106.8 CHF 0.38% Market Closed
Market Cap: 2.1B CHF
Have any thoughts about
Medacta Group SA?
Write Note

Medacta Group SA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medacta Group SA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Medacta Group SA
SIX:MOVE
Depreciation & Amortization
€58.4m
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Metall Zug AG
SIX:METN
Depreciation & Amortization
CHf10.9m
CAGR 3-Years
-15%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Sonova Holding AG
SIX:SOON
Depreciation & Amortization
CHf245.3m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
19%
Straumann Holding AG
SIX:STMN
Depreciation & Amortization
CHf130.2m
CAGR 3-Years
9%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Medmix Ltd
SIX:MEDX
Depreciation & Amortization
CHf58.4m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
No Stocks Found

Medacta Group SA
Glance View

Market Cap
2.1B CHF
Industry
Health Care

Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients. Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.

MOVE Intrinsic Value
124.9 CHF
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Medacta Group SA's Depreciation & Amortization?
Depreciation & Amortization
58.4m EUR

Based on the financial report for Dec 31, 2023, Medacta Group SA's Depreciation & Amortization amounts to 58.4m EUR.

What is Medacta Group SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
19%

Over the last year, the Depreciation & Amortization growth was 13%. The average annual Depreciation & Amortization growth rates for Medacta Group SA have been 16% over the past three years , 19% over the past five years .

Back to Top